natalizumab
biogen
['natalizumab']
kalincik: msbase study compared ahsct vs natalizumab in progressive ms (ppms and spms). on a group level no difference in relapse rate or disability worsening or improvement was seen. limitation is ao low number of pts (39 ahsct pts) studied.
#ectrims2022 
Professor Dr Bart Van Wijmeersch
Neurologist, Immunologist
#MultipleSclerosis Expert
@ University MS Centre, Hasselt-Pelt, Belgium